Nasal Polyps Treatment Market, by Drug Class, (Corticosteroids, (Nasal corticosteroids, Fluticasone, Budesonide, Mometasone, Triamcinolone, Others - Beclomethasone, Ciclesonide, etc.), Oral/Injectable Corticosteroids (Prednisone, Combination), Antibiotics

Nasal Polyps Treatment Market, by Drug Class, (Corticosteroids, (Nasal corticosteroids, Fluticasone, Budesonide, Mometasone, Triamcinolone, Others - Beclomethasone, Ciclesonide, etc.), Oral/Injectable Corticosteroids (Prednisone, Combination), Antibiotics, Antihistamines, Interleukin Inhibitors, (Dupilumab, Others (IL 10, IL 25 etc.)), Monoclonal Antibodies, (Mepolizumab, Omalizumab, Others), Others (Aspirin, anticholinergic agent and etc.)), by Route of Administration (Nasal, Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Nasal polyps develop in swollen tissue of the nasal mucosa. The mucosa is a very wet layer that protects the inside of nose and sinuses. During a contamination or allergy-induced irritation, the nasal mucosa becomes swollen and red, and it produces liquid that drips out. With prolonged irritation, the mucosa can form a polyp. A nasal polyp is a round growth that can block nasal passages.

Nasal polyps grow large enough that may to block nasal passages, which causes chronic congestion. Its system includes a sensation like block nose, runny nose, a feeling of pressure in forehead or face nasal stuffiness, nasal congestion, reduced sense of smell etc. Medications that decrease swelling may help reduce the size of the polyp and dismiss symptoms of congestion. Spraying nasal steroids into the nose can decrease runny nose and the sensation of block by reduction the nasal polyp. If nasal polyps are not cured with drugs, surgery can eliminate the nasal polyps totally.

Market Dynamics

Market players are getting approvals from regulatory bodies to develop new therapy for the treatment of nasal polys, which is expected to drive growth of the global nasal polyps treatment market, over the forecast period. For instance, according to data published in SAGE Journals, a publishing company, as on October 9, 2020, the U.S. Food and Drug Administration had approved biologic therapy as a new treatment for the patients suffering with chronic rhinosinusitis with nasal polyps. Biologics aim and reduce type 2 cytokine inflammation, and is one of the novel treatment opportunities for patients with chronic rhinosinusitis with nasal polyps.

Increasing prevalence of sinuses related diseases is expected to drive growth of the global nasal polyps treatment market, over the forecast period. For instance, according to report of 2018 by Centers for Disease Control and Prevention, in the U.S. about 28.9 million people above age 18 were diagnosed with sinusitis. Sinusitis is an inflammation of the tissue lining the sinuses. Increase in number of sinusitis disease among the population would result in high demand for the treatment, which would drive growth of the nasal polyps treatment market

Key features of the study:

• This report provides an in-depth analysis of the global nasal polyps treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global nasal polyps treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Regeneron Pharmaceuticals, Inc., Hoffmann-La Roche Ag, Fougera Pharmaceuticals Inc., Novartis International Ag, Sanofi S.A., GlaxoSmithKline Plc, Intersect Ent, Dohme Corp, Merck & Co., Inc., Sanofi S.A., Norton Waterford Ltd, Astrazeneca Plc, Taro Pharmaceuticals Industries Ltd., Teva Pharmaceutical Industries Limited, and OptiNose Inc.
• Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global nasal polyps treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal polyps treatment market.

Detailed Segmentation:

• Global Nasal Polyps Treatment Market, By Drug Class:
• Corticosteroids
• Nasal corticosteroids
• Fluticasone
• Budesonide
• Mometasone
• Triamcinolone
• Others - Beclomethasone, Ciclesonide, etc.
• Oral/Injectable Corticosteroids
• Prednisone
• Combination
• Antibiotics
• Antihistamines
• Interleukin Inhibitors
• Dupilumab
• Others (IL 10, IL 25 etc.)
• Monoclonal Antibodies
• Mepolizumab
• Omalizumab
• Others
• Others (Aspirin, anticholinergic agent and etc.)
• Global Nasal Polyps Treatment Market, By Route of Administration:
• Nasal
• Oral
• Parenteral
• Global Nasal Polyps Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Nasal Polyps Treatment Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• Asia Pacific
• By Country:
• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Regeneron Pharmaceuticals, Inc *
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
• Hoffmann-La Roche Ag
• Fougera Pharmaceuticals Inc.,
• Novartis International Ag
• Sanofi S.A.
• GlaxoSmithKline Plc
• Intersect Ent
• Dohme Corp
• Merck & Co., Inc.
• Norton Waterford Ltd
• Astrazeneca Plc
• Taro Pharmaceuticals Industries Ltd.
• Teva Pharmaceutical Industries Limited
• OptiNose Inc.

“*” marked represents similar segmentation in other categories in the respective section.